GPN Vaccines develops vaccines to protect adults and children from bacterial pathogens.

GPN Vaccines

GPN Vaccines is a clinical-stage company focused on creating innovative vaccines that offer robust protection against the world's most important bacterial pathogens.

Government of South Australia

National Health and Medical Research Council

Forepont Capital Partners

We are delighted to support Carla Gallasch as the University of Adelaide's first PhD student to be awarded a National Industry PhD Program Scholarship! 

Building on years of know how and learnings from the Gamma-PN program, Carla is working on a new vaccine to provide protection against Haemophilus influenzae - a major cause of ear infections in children.

GPN Vaccines is building its clinical team and is seeking an experienced Clinical Project Manager to work with our Chief Medical Officer. 

The role can be either full or part-time depending on experience and remote candidates are encouraged to apply. 

Industry experience is essential, and those with GCP training and a track record of running vaccine studies will be highly regarded.

Team lunches are getting bigger at GPN Vaccines! 

Celebrating the retirement of Professor James Paton and Leigh Willis who have both made invaluable contributions to the company, and welcoming new staff and students Chloe Gates, Ricky Williams, Brooke Dilmetz, Janice Henrichs and Mariana Couto Moniz.

We are pleased to announce the award of AUD$936,000 to GPN Vaccines in Round 3 of the CUREator Program! 

This funding will be used to support investigation of the durability of Gamma-PN's immune response in adults. 

Thank you to Brandon Capital and supporters CSIRO and Australian Government Department of Health and Aged Care for this important funding.

Congratulations Chloe Gates and welcome (officially) to the team! We look forward to building on the great work you did with us during your PhD as well as working on some exciting new projects!

We are humbled to have been invited to write a short review paper for Vaccine Insights recently titled 'Whole-cell pneumococcal vaccines: a future-proof approach to overcoming serotype replacement". 

Take a look if you are interested in learning more about our approach. 

Thanks for the opportunity BioInsights!

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Aug 7, 2024 8:08 AM	ace38122
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	196f251b
crunchbase profile	general
li profile	general	Aug 7, 2024 8:08 AM	fd650a12
translate crunchbase fundingrounds	general
peers	general	Aug 7, 2024 8:08 AM	8013ed01
news basic	general	Aug 7, 2024 8:08 AM	6a0f8770
bundesanzeiger	filings
financials download nd	financials
private financials	financials

GPNV

COM:GPNVACCINES

GPN Vaccines